| Ytd | 35.71% | |
| 1y | 42.27% |
| Open | 5.40 | Prev Close | 5.47 | Low | 5.31 | High | 6.04 | Mkt Cap | 79.33M |
| Vol | 393.89K | Avg Vol | 559.43K | EPS | -4.33 | P/E | N/A | Forward P/E | -0.65 |
| Beta | -0.91 | Short Ratio | 0.69 | Inst. Own | 1.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.88 | 200-d Avg | 5.00 | 1yr Est | 48.33 |
CING News
Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the
The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests an
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst cons
Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lower
Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.84) per share which missed the analyst cons
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lower
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of nex
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of nex
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raise
Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the
Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst cons
Jennifer Callahan, Chief Financial Officer, appointed Interim CEOBoard member, Jay Roberts appointed
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lower
Details of the FDA's minutes include the following, all of which will be a matter of review duri
Cingulate (NASDAQ:CING) reported quarterly losses of $(1.04) per share which missed the analyst cons
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Wid
KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceuti
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cingulate (NASDAQ:CING) with a Buy a
Roth MKM analyst Boobalan Pachaiyappan initiates coverage on Cingulate (NASDAQ:CING) with a Buy r
Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the comp
Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a
Monday's session saw 175 companies set new 52-week lows.